Cosmetic uses of substances of very high concern are excluded from authorization requirements under EU REACH when the substance was listed strictly for endocrine-disrupting concerns. However, cosmetic product manufacturers may find the preservative unavailable from suppliers should butylparaben eventually make the European Chemicals Agency’s Authorization List.
The European Chemicals Agency announced on 25 June that it has added butyl 4-hydroxybenzoate (butylparaben) to the Candidate List for authorization under the EU’s Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) regulation.
The move does not mean that butylparaben’s days are numbered as one of the cosmetic industry’s remaining preservative go-to’s, but...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
